P/B
0,8
CorMedix
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
$370.6M
Market Cap • 11/13/2026
2006
(20 years)
Founded
2010
(16 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
0,9
P/EBITDA
1,8
P/OCF
1,2
P/FCF
1,2
P/E
6,8
BVPS
5,8
EPS
0,7
Market Cap
Market Cap
370,6M
EV
160,9M
EV/Revenue
0,4
EV/EBITDA
0,8
EV/EBIT
1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,5%
Total Yield
0,5%
Payout
0%
Retained Earnings
-126,7M
Profitability
Gross Margin
77,5%
EBITDA Margin
49%
EBIT Margin
38,6%
Net Margin
15,5%
D&A/EBITDA
0%
R&D/Revenue
-12,4%
Capex/Revenue
1,2%
Capex/D&A
11,4%
Capex/OCF
1,6%
SBC/OCF
5,2%
% PPE
0,9%
% Goodwill
3,3%
ROE
15,3%
ROIC
22,7%
Growth
CAGR Revenue 5Y
364,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,4
Quick Ratio
2,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!